Supernus Pharmaceuticals, Inc.
SUPN
Clasificación en acciones
#5698
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Precio por acción
$39.99
Última sincronización: 2026-10-19
Capitalización bursátil
$2.33B
Cambio (1 día)
5.58%
Cambio (1 año)
-22.01%
País
US
Comercio Supernus Pharmaceuticals, Inc. (SUPN)
Categoría
Healthcare
Historial de dividendos de Supernus Pharmaceuticals, Inc. (SUPN)
Supernus Pharmaceuticals, Inc. (símbolo bursátil: SUPN) realizó un total de 0 pagos de dividendos.
La suma de todos los dividendos (ajustados por splits de acciones) es: 0.00
Rentabilidad por dividendo (TTM): 0
La suma de todos los dividendos (ajustados por splits de acciones) es: 0.00
Rentabilidad por dividendo (TTM): 0
Pagos de dividendos de Supernus Pharmaceuticals, Inc. (SUPN) desde 2026 hasta 2026
Pagos anuales de dividendos
| Año | Dividendo (ajustado por splits de acciones) | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Lista de todos los pagos de dividendos
| Año | Dividendo | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Pagos de dividendos de empresas similares o competidoras
| Empresa | Número de pagos de dividendos | País |
|---|---|---|
| 0.00% |
DE
|
|
| 0.00% |
DE
|
|
| 0.00% |
JP
|
|
| 0.00% |
CH
|
|
| 38.00% |
IN
|
